SIETES :: 93213 citas

Resultados de la búsqueda por HIPERTRIGLICERIDEMIA REFINAR BÚSQUEDA

1.

Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]

2.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]

3.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

4.

Roehr B. Court rules that FDA cannot restrict off-label marketing. BMJ 2015;351:h4367. [Ref.ID 99403]

5.

Anónimo. Pharmaceutical manufacturer preemptively sues FDA over right to discuss off-label uses. DIA Daily 2015:8 de mayo. [Ref.ID 99039]

6.

Anónimo. Icosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther 2013;55:33-4. [Ref.ID 95656]

7.

Anónimo. Drugs for hypertriglyceridemia. Med Lett Drugs Ther 2013;55:17-9. [Ref.ID 95162]

8.

Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence?. Ann Intern Med 2012;157:662-4. [Ref.ID 94014]

9.

Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardiff CM, Rudd JHF, Farkouh ME, Tawakol A, for the dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. [Ref.ID 91765]

10.

Stroes ESG, van Wijk DF. Dalcetrapib: turning the tide for CETP inhibition?. Lancet 2011;378:1529. [Ref.ID 91763]

11.

Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias - Time for a reassessment. N Engl J Med 2011;365:481-4. [Ref.ID 91479]

12.

Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011;34:651-68. [Ref.ID 91086]

13.

Krumholz H. Five lessons from Niaspan's dissappointing study. Journal Watch 2011;31:7 de junio. [Ref.ID 90732]

14.

Anónimo. Everolimus and pazopanib: two new drugs for renal cell cancer. Med Lett Drugs Ther 2010;52:33-4. [Ref.ID 88491]

15.

Varley C, McClellan J. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730-1. [Ref.ID 87923]

16.

Correll CU, Kane JM, Malhotra AK. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730. [Ref.ID 87922]

17.

Lewin AB, Stroch EA, Storch HD. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729-30. [Ref.ID 87921]

18.

Mangurian C, Fuentes-Afflick E, Newcomer JW. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729. [Ref.ID 87920]

19.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. [Ref.ID 86924]

20.

Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults. Invited commentary. Arch Intern Med 2009;169:578-9. [Ref.ID 85598]